達安基因(002030.SZ):公司主要核心原材料均是自主開發和生產
格隆匯11月16日丨達安基因(002030.SZ)近期在接待機構投資者調研時表示,隨着產品的規模化生產,公司可以更有效地控制生產成本。而且公司主要核心原材料均是自主開發和生產,基本不依賴外部供應商,可在最短時間內供給產品研製及大規模生產所必須的關鍵物料包括逆轉錄酶、熱啟動酶等。自主設計和生產原材料,這也減少了中間環節和交易成本,降低了企業的採購成本。從而,國內先進水平的工藝技術及規模效應化降低了生產成本,進一步提高產品的性價比。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.